Solnul®
Sky Checotah currently serves as the Director of Business Development - North America at Solnul® since June 2025. Prior experience includes the role of East Coast Sales and Business Manager at HP Ingredients from February 2022 to June 2025, and Account Executive positions at Akumin® (July 2019 - February 2022) and MiMedx (July 2014 - June 2019), where responsibilities included managing substantial sales in Advanced Biologics and providing account management for federal clients. Additionally, Sky held an Account Executive position at Elara Health from June 2017 to February 2019, focusing on clinical liaison services and training healthcare professionals. Sky Checotah holds a Bachelor of Science in Biology from Oklahoma State University and a Master of Science in Kinesiology and Exercise Science from the University of Central Oklahoma.
This person is not in any teams
This person is not in any offices
Solnul®
Solnul® is a prebiotic resistant starch ingredient that selectively feeds Bifidobacterium to support optimal digestion and GI health. Backed by a body of clinical and scientific research, Solnul® is raising the bar for the prebiotic and resistant starch categories. It demonstrates prebiotic benefits like increases in Bifidobacterium and Akkermansia, and improvements in IBS-related symptoms, regularity, and metabolic health – all at low doses. Using metabolite research findings, it is among the first prebiotics to show total body effects "Beyond the Gut," through the Gut/Skin and Gut/Brain axes. It has several substantiated structure/function claims brands can utilize to capture the growing demand for resistant starch products. By partnering with Solnul®, you'll gain access to human microbiome research, patent portfolio, industry insights and exclusive claims for dietary supplement and functional food and beverage applications. For more information on formulating with Solnul®, please visit Solnul.com.